Does OLAPARIB Cause Interstitial lung disease? 370 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 370 reports of Interstitial lung disease have been filed in association with OLAPARIB (Lynparza). This represents 2.0% of all adverse event reports for OLAPARIB.
370
Reports of Interstitial lung disease with OLAPARIB
2.0%
of all OLAPARIB reports
21
Deaths
124
Hospitalizations
How Dangerous Is Interstitial lung disease From OLAPARIB?
Of the 370 reports, 21 (5.7%) resulted in death, 124 (33.5%) required hospitalization, and 17 (4.6%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 370 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which OLAPARIB Alternatives Have Lower Interstitial lung disease Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL